Immune checkpoint inhibitors, including monoclonal antibodies targeting cytotoxic T lymphocyte-associated antigen 4 (CTLA4), programmed cell death 1 (PD1), or PD1 ligand (PD-L1), are effective in the treatment of various types of cancer, especially melanoma and lung cancer [1]. This evidence concerns the gene PDCD1 and lung carcinoma.